Medtronic (NYSE:MDT) this week touted results from a three-month clinical trial of the recently acquired Stimgenics Differential Target Multiplexed Spinal Cord Stimulation using Medtronic’s Intellis platform.
The large, multicenter randomized controlled trial showed that 80% of patients with chronic back pain that were treated with Differential Target Multiplexed (DTM) reported at least 50% pain relief in comparison with 51% of patients that were treated with conventional spinal cord stimulation.
Trial results also showed that there was “profound pain relief and a significant reduction in back and leg pain” using the DTM technology, according to Medtronic. About 63% of back pain patients reported pain relief of 80% or greater compared to 26% that were treated with conventional spinal cord stimulation. Other patients treated with DTM reported an average 74% reduction in back pain, compared to 46% with conventional spinal cord stimulation at three months.
Medtronic acquired the DTM technology in its acquisition of Stimgenics earlier this month for an undisclosed amount.
“DTM therapy is the first tailored SCS approach intentionally developed from a novel scientific concept and demonstrated in an RCT. The study demonstrates that DTM therapy provides superior efficacy for patients with chronic back pain compared to conventional stimulation,” VP and general manager of stim and early interventions at Medtronic Matt Thomas said in a news release. “Combined with Intellis, patients can access superior outcomes as demonstrated in the RCT on an unrivaled stimulation platform.”
The company plans to continue the trial up to 12 months after the Intellis implant.
Intellis is an implantable neurostimulator that adjusts stimulation based on a patient’s needs and preferences in different body positions. The newly acquired DTM technology modulates both neurons and glial cells.